| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder | 39 | 2024 | 1171 | 4.600 |
Why?
|
| Muscle, Smooth | 25 | 2022 | 933 | 3.290 |
Why?
|
| Spinal Cord Injuries | 8 | 2020 | 930 | 2.120 |
Why?
|
| Neuropilin-2 | 4 | 2022 | 54 | 2.010 |
Why?
|
| Myocytes, Smooth Muscle | 13 | 2024 | 686 | 1.860 |
Why?
|
| Inosine | 3 | 2018 | 133 | 1.690 |
Why?
|
| Muscle Contraction | 9 | 2022 | 1241 | 1.510 |
Why?
|
| Urinary Bladder Neoplasms | 12 | 2022 | 2229 | 1.440 |
Why?
|
| Urothelium | 11 | 2019 | 277 | 1.440 |
Why?
|
| Platelet-Derived Growth Factor | 7 | 2015 | 625 | 1.160 |
Why?
|
| Carcinoma, Transitional Cell | 7 | 2022 | 798 | 1.050 |
Why?
|
| Epidermal Growth Factor | 20 | 2005 | 709 | 0.930 |
Why?
|
| Urinary Bladder, Overactive | 4 | 2024 | 106 | 0.910 |
Why?
|
| Urinary Bladder Diseases | 4 | 2020 | 166 | 0.910 |
Why?
|
| Gastrointestinal Motility | 1 | 2022 | 225 | 0.760 |
Why?
|
| Proto-Oncogene Proteins c-akt | 10 | 2017 | 2502 | 0.740 |
Why?
|
| Urinary Bladder Neck Obstruction | 4 | 2017 | 80 | 0.710 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2018 | 165 | 0.670 |
Why?
|
| Tissue Scaffolds | 7 | 2014 | 957 | 0.670 |
Why?
|
| Membrane Microdomains | 8 | 2008 | 202 | 0.640 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 22 | 2012 | 1675 | 0.640 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2011 | 575 | 0.630 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2017 | 124 | 0.570 |
Why?
|
| Systems Biology | 1 | 2020 | 469 | 0.550 |
Why?
|
| Fibroins | 4 | 2021 | 55 | 0.540 |
Why?
|
| Silk | 5 | 2014 | 87 | 0.520 |
Why?
|
| Host vs Graft Reaction | 1 | 2014 | 14 | 0.520 |
Why?
|
| Cell Separation | 1 | 2020 | 1749 | 0.490 |
Why?
|
| Mucous Membrane | 1 | 2018 | 670 | 0.480 |
Why?
|
| Colon | 1 | 2022 | 1773 | 0.480 |
Why?
|
| Regeneration | 10 | 2021 | 1485 | 0.480 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 808 | 0.470 |
Why?
|
| Glycoproteins | 4 | 2010 | 2260 | 0.460 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2022 | 2940 | 0.450 |
Why?
|
| Actins | 4 | 2013 | 2120 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2017 | 987 | 0.440 |
Why?
|
| Cystitis, Interstitial | 2 | 2024 | 61 | 0.440 |
Why?
|
| Cyclin A1 | 1 | 2012 | 11 | 0.430 |
Why?
|
| Rats | 24 | 2021 | 24265 | 0.420 |
Why?
|
| Laminectomy | 1 | 2013 | 232 | 0.420 |
Why?
|
| Biocompatible Materials | 5 | 2014 | 1731 | 0.420 |
Why?
|
| Evoked Potentials | 1 | 2018 | 1057 | 0.410 |
Why?
|
| Transcription Factors | 6 | 2024 | 12164 | 0.410 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2013 | 644 | 0.400 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2015 | 2915 | 0.390 |
Why?
|
| GATA6 Transcription Factor | 2 | 2010 | 50 | 0.390 |
Why?
|
| Spinal Cord Compression | 1 | 2013 | 235 | 0.390 |
Why?
|
| Growth Substances | 4 | 2005 | 783 | 0.390 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2013 | 849 | 0.380 |
Why?
|
| Nuclear Proteins | 2 | 2024 | 5851 | 0.370 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2022 | 2938 | 0.370 |
Why?
|
| Animals | 64 | 2022 | 168561 | 0.360 |
Why?
|
| Ureter | 3 | 2015 | 374 | 0.360 |
Why?
|
| Thrombomodulin | 1 | 2010 | 102 | 0.350 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 2183 | 0.350 |
Why?
|
| Signal Transduction | 26 | 2021 | 23387 | 0.340 |
Why?
|
| Tissue Engineering | 7 | 2017 | 1877 | 0.340 |
Why?
|
| Chromosome Deletion | 2 | 2010 | 1400 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2010 | 537 | 0.330 |
Why?
|
| Endopeptidases | 1 | 2012 | 772 | 0.320 |
Why?
|
| Transforming Growth Factor beta | 3 | 2024 | 2006 | 0.320 |
Why?
|
| Cell Fractionation | 1 | 2008 | 252 | 0.310 |
Why?
|
| Myristic Acid | 1 | 2007 | 47 | 0.310 |
Why?
|
| Cell Movement | 5 | 2014 | 5212 | 0.310 |
Why?
|
| Transcription Factor AP-1 | 5 | 2014 | 317 | 0.300 |
Why?
|
| Isometric Contraction | 2 | 2018 | 147 | 0.300 |
Why?
|
| Carcinoma | 4 | 2013 | 2374 | 0.300 |
Why?
|
| Cells, Cultured | 22 | 2024 | 19223 | 0.300 |
Why?
|
| Disease Models, Animal | 10 | 2017 | 18006 | 0.290 |
Why?
|
| Urodynamics | 4 | 2017 | 347 | 0.290 |
Why?
|
| Cyclooxygenase 2 | 2 | 2007 | 611 | 0.290 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2009 | 113 | 0.290 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2005 | 697 | 0.280 |
Why?
|
| Keratin-5 | 2 | 2017 | 46 | 0.270 |
Why?
|
| rho-Associated Kinases | 4 | 2013 | 279 | 0.270 |
Why?
|
| Cholesterol | 5 | 2007 | 2895 | 0.270 |
Why?
|
| Telomerase | 1 | 2010 | 729 | 0.270 |
Why?
|
| Mice | 36 | 2022 | 81045 | 0.260 |
Why?
|
| Proteomics | 4 | 2020 | 3618 | 0.250 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 789 | 0.250 |
Why?
|
| Caveolae | 1 | 2004 | 57 | 0.250 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2005 | 452 | 0.240 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2021 | 8300 | 0.240 |
Why?
|
| Cytoskeleton | 2 | 2024 | 1185 | 0.240 |
Why?
|
| Prostatic Neoplasms | 17 | 2015 | 11039 | 0.240 |
Why?
|
| Genomics | 1 | 2020 | 5692 | 0.240 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 9410 | 0.230 |
Why?
|
| Bladder Exstrophy | 1 | 2005 | 106 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2017 | 8425 | 0.230 |
Why?
|
| Caspases | 2 | 2007 | 928 | 0.220 |
Why?
|
| Cell Survival | 6 | 2020 | 5872 | 0.220 |
Why?
|
| Phosphorylation | 12 | 2015 | 8436 | 0.220 |
Why?
|
| Humans | 88 | 2024 | 742088 | 0.220 |
Why?
|
| Prostate | 8 | 2008 | 1764 | 0.210 |
Why?
|
| Carbachol | 1 | 2022 | 226 | 0.210 |
Why?
|
| Enzyme Inhibitors | 7 | 2005 | 3800 | 0.210 |
Why?
|
| Synaptotagmin II | 1 | 2021 | 15 | 0.210 |
Why?
|
| Gene Expression Regulation | 6 | 2013 | 12071 | 0.210 |
Why?
|
| RNA, Messenger | 13 | 2024 | 13029 | 0.210 |
Why?
|
| Subrenal Capsule Assay | 1 | 2001 | 26 | 0.200 |
Why?
|
| Synaptotagmin I | 1 | 2021 | 36 | 0.200 |
Why?
|
| Stress, Mechanical | 7 | 2005 | 1684 | 0.200 |
Why?
|
| Membrane Proteins | 6 | 2018 | 7873 | 0.200 |
Why?
|
| Caveolin 1 | 3 | 2013 | 264 | 0.190 |
Why?
|
| Prostatic Hyperplasia | 3 | 2003 | 522 | 0.190 |
Why?
|
| Urinary Tract | 2 | 2015 | 308 | 0.190 |
Why?
|
| Amides | 1 | 2003 | 458 | 0.190 |
Why?
|
| T-Box Domain Proteins | 2 | 2015 | 471 | 0.190 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2007 | 1337 | 0.190 |
Why?
|
| Androgens | 4 | 2007 | 1271 | 0.190 |
Why?
|
| Cell Line | 7 | 2017 | 15994 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2013 | 4553 | 0.180 |
Why?
|
| Receptors, Androgen | 5 | 2013 | 1057 | 0.180 |
Why?
|
| Botulinum Toxins | 1 | 2021 | 192 | 0.180 |
Why?
|
| Phenotype | 4 | 2020 | 16331 | 0.170 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2019 | 34 | 0.170 |
Why?
|
| Arsenic | 1 | 2022 | 328 | 0.170 |
Why?
|
| Shiga Toxins | 1 | 2018 | 41 | 0.170 |
Why?
|
| Neoplasm Metastasis | 5 | 2017 | 4839 | 0.170 |
Why?
|
| Ricin | 1 | 2018 | 72 | 0.170 |
Why?
|
| Muscle Relaxation | 2 | 2011 | 142 | 0.160 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2018 | 109 | 0.160 |
Why?
|
| Cell Proliferation | 9 | 2019 | 10472 | 0.160 |
Why?
|
| Tretinoin | 2 | 2011 | 516 | 0.160 |
Why?
|
| Perioperative Period | 1 | 2019 | 256 | 0.150 |
Why?
|
| Calibration | 1 | 2020 | 815 | 0.150 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2021 | 427 | 0.150 |
Why?
|
| Apoptosis | 9 | 2019 | 9715 | 0.150 |
Why?
|
| Receptors, Muscarinic | 1 | 2018 | 156 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 2 | 2022 | 170 | 0.150 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2017 | 48 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 9 | 2013 | 6313 | 0.150 |
Why?
|
| Xanthines | 1 | 2017 | 121 | 0.150 |
Why?
|
| Cell Line, Tumor | 13 | 2019 | 16665 | 0.150 |
Why?
|
| Cobalt | 1 | 2017 | 158 | 0.140 |
Why?
|
| TRPV Cation Channels | 3 | 2015 | 235 | 0.140 |
Why?
|
| Benchmarking | 1 | 2022 | 1038 | 0.140 |
Why?
|
| Myosin Light Chains | 2 | 2013 | 121 | 0.140 |
Why?
|
| RNA, Small Interfering | 4 | 2013 | 3504 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2009 | 4751 | 0.130 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2018 | 625 | 0.130 |
Why?
|
| Perfusion | 1 | 2020 | 1359 | 0.130 |
Why?
|
| Stromal Cells | 3 | 2017 | 1353 | 0.130 |
Why?
|
| Synaptophysin | 1 | 2015 | 141 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2016 | 3502 | 0.130 |
Why?
|
| Cell Division | 10 | 2009 | 4564 | 0.130 |
Why?
|
| Transfection | 7 | 2013 | 5892 | 0.130 |
Why?
|
| DNA | 4 | 2005 | 7289 | 0.130 |
Why?
|
| Neuromuscular Junction | 1 | 2018 | 397 | 0.130 |
Why?
|
| Chromium | 1 | 2016 | 123 | 0.130 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 786 | 0.130 |
Why?
|
| Intestinal Mucosa | 3 | 2014 | 3038 | 0.130 |
Why?
|
| Esophagus | 1 | 2021 | 1017 | 0.130 |
Why?
|
| Bombyx | 2 | 2013 | 55 | 0.130 |
Why?
|
| Triazines | 1 | 2017 | 316 | 0.130 |
Why?
|
| Chromosomal Instability | 1 | 2016 | 184 | 0.130 |
Why?
|
| Gene Silencing | 4 | 2015 | 1538 | 0.130 |
Why?
|
| Fibroblast Growth Factor 2 | 4 | 2003 | 599 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-sis | 3 | 2004 | 251 | 0.120 |
Why?
|
| Epigenomics | 1 | 2020 | 902 | 0.120 |
Why?
|
| Hepatectomy | 2 | 2019 | 550 | 0.120 |
Why?
|
| Guided Tissue Regeneration | 1 | 2014 | 85 | 0.120 |
Why?
|
| Embryonic Stem Cells | 2 | 2013 | 1294 | 0.120 |
Why?
|
| Down-Regulation | 3 | 2012 | 3001 | 0.120 |
Why?
|
| Potassium Channels | 1 | 2017 | 562 | 0.120 |
Why?
|
| Flow Cytometry | 4 | 2020 | 5975 | 0.120 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 3 | 2010 | 428 | 0.120 |
Why?
|
| Paracrine Communication | 1 | 2015 | 276 | 0.120 |
Why?
|
| Neurofilament Proteins | 1 | 2015 | 318 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2022 | 4029 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2014 | 286 | 0.120 |
Why?
|
| Urologic Surgical Procedures | 2 | 2013 | 301 | 0.120 |
Why?
|
| Mitral Valve | 1 | 2022 | 1484 | 0.110 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2013 | 45 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 4 | 2015 | 2699 | 0.110 |
Why?
|
| Cell Nucleus | 4 | 2008 | 2968 | 0.110 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2013 | 44 | 0.110 |
Why?
|
| Myosin-Light-Chain Phosphatase | 1 | 2013 | 20 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 2867 | 0.110 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2013 | 43 | 0.110 |
Why?
|
| Male | 38 | 2021 | 349538 | 0.110 |
Why?
|
| Muscle Proteins | 2 | 2013 | 1159 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2022 | 2906 | 0.110 |
Why?
|
| DNA-Binding Proteins | 5 | 2019 | 9639 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 2009 | 4229 | 0.110 |
Why?
|
| Pyridines | 2 | 2003 | 2818 | 0.110 |
Why?
|
| Genes, Dominant | 1 | 2015 | 880 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 1740 | 0.110 |
Why?
|
| Kidney | 2 | 2005 | 7167 | 0.100 |
Why?
|
| Polymerization | 1 | 2013 | 163 | 0.100 |
Why?
|
| Neoplasm Transplantation | 3 | 2006 | 2085 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 3 | 2013 | 874 | 0.100 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2013 | 270 | 0.100 |
Why?
|
| Cell Membrane | 3 | 2007 | 3744 | 0.100 |
Why?
|
| Taxoids | 1 | 2015 | 665 | 0.100 |
Why?
|
| Urethra | 1 | 2014 | 408 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 5 | 2004 | 1284 | 0.100 |
Why?
|
| Up-Regulation | 4 | 2012 | 4211 | 0.100 |
Why?
|
| Tenascin | 1 | 2011 | 59 | 0.100 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2011 | 96 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 4465 | 0.100 |
Why?
|
| Epithelial Cells | 7 | 2021 | 3678 | 0.100 |
Why?
|
| Neurosecretory Systems | 2 | 2003 | 231 | 0.100 |
Why?
|
| Triazoles | 1 | 2017 | 907 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 1707 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2012 | 264 | 0.100 |
Why?
|
| Fibroblast Growth Factor 8 | 1 | 2011 | 61 | 0.100 |
Why?
|
| Cell Shape | 1 | 2012 | 375 | 0.100 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2012 | 241 | 0.100 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 168 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 2 | 2015 | 1655 | 0.090 |
Why?
|
| Wound Healing | 3 | 2018 | 2781 | 0.090 |
Why?
|
| Disease Progression | 5 | 2019 | 13256 | 0.090 |
Why?
|
| Sus scrofa | 1 | 2012 | 437 | 0.090 |
Why?
|
| Liver Neoplasms | 2 | 2019 | 4249 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3471 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2013 | 551 | 0.090 |
Why?
|
| Detergents | 2 | 2008 | 230 | 0.090 |
Why?
|
| Mice, Knockout | 3 | 2022 | 14554 | 0.090 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 295 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2017 | 3617 | 0.090 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2010 | 180 | 0.090 |
Why?
|
| Facial Bones | 1 | 2011 | 201 | 0.090 |
Why?
|
| Lymphedema | 1 | 2016 | 528 | 0.090 |
Why?
|
| GATA4 Transcription Factor | 1 | 2010 | 130 | 0.090 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2009 | 15 | 0.090 |
Why?
|
| Microtubules | 1 | 2015 | 1090 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 3557 | 0.080 |
Why?
|
| Cell Differentiation | 7 | 2017 | 11470 | 0.080 |
Why?
|
| Cell Culture Techniques | 2 | 2010 | 1670 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 6 | 2013 | 5867 | 0.080 |
Why?
|
| Immunohistochemistry | 8 | 2015 | 11363 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2009 | 199 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2011 | 473 | 0.080 |
Why?
|
| Species Specificity | 1 | 2013 | 2479 | 0.080 |
Why?
|
| Mice, SCID | 3 | 2005 | 2715 | 0.080 |
Why?
|
| Solubility | 2 | 2017 | 1083 | 0.080 |
Why?
|
| PPAR gamma | 1 | 2011 | 493 | 0.080 |
Why?
|
| Cell Growth Processes | 2 | 2006 | 400 | 0.080 |
Why?
|
| Calcium Channels | 2 | 2002 | 621 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 1081 | 0.080 |
Why?
|
| Microarray Analysis | 1 | 2010 | 766 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2017 | 1932 | 0.070 |
Why?
|
| Mitogens | 3 | 2003 | 232 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2013 | 1905 | 0.070 |
Why?
|
| Subcellular Fractions | 1 | 2008 | 547 | 0.070 |
Why?
|
| Cyclodextrins | 1 | 2007 | 57 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 663 | 0.070 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 1152 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2012 | 2003 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 2019 | 6754 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 3639 | 0.070 |
Why?
|
| Skull | 1 | 2011 | 810 | 0.070 |
Why?
|
| Muscles | 1 | 2011 | 1617 | 0.070 |
Why?
|
| Female | 22 | 2021 | 379592 | 0.070 |
Why?
|
| Enzyme Activation | 4 | 2008 | 3701 | 0.070 |
Why?
|
| Phosphopyruvate Hydratase | 2 | 2003 | 135 | 0.070 |
Why?
|
| Models, Animal | 3 | 2021 | 2170 | 0.070 |
Why?
|
| Interleukin-6 | 3 | 2004 | 3199 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2021 | 3731 | 0.070 |
Why?
|
| Caspase 9 | 1 | 2005 | 188 | 0.070 |
Why?
|
| Phenanthridines | 1 | 2005 | 51 | 0.070 |
Why?
|
| Neuropilin-1 | 1 | 2005 | 90 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 2186 | 0.060 |
Why?
|
| Fibroblast Growth Factor 9 | 1 | 2004 | 13 | 0.060 |
Why?
|
| Culture Media, Conditioned | 2 | 2005 | 533 | 0.060 |
Why?
|
| Zinc Fingers | 1 | 2007 | 585 | 0.060 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2004 | 61 | 0.060 |
Why?
|
| Receptor, PAR-2 | 1 | 2004 | 32 | 0.060 |
Why?
|
| Dihydrotestosterone | 2 | 2002 | 188 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2007 | 320 | 0.060 |
Why?
|
| Binding Sites | 3 | 2009 | 6115 | 0.060 |
Why?
|
| Transcription, Genetic | 3 | 2013 | 7721 | 0.060 |
Why?
|
| Quantum Dots | 1 | 2006 | 172 | 0.060 |
Why?
|
| Hypertrophy | 2 | 2003 | 568 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 3 | 2013 | 2458 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 2006 | 1902 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2012 | 2751 | 0.060 |
Why?
|
| Cell Physiological Phenomena | 1 | 2005 | 154 | 0.060 |
Why?
|
| Multiple Sclerosis | 1 | 2018 | 3076 | 0.060 |
Why?
|
| DNA Primers | 5 | 2011 | 2892 | 0.060 |
Why?
|
| Organ Culture Techniques | 1 | 2006 | 808 | 0.060 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2004 | 283 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2008 | 2203 | 0.060 |
Why?
|
| Cardiovascular System | 1 | 2011 | 827 | 0.060 |
Why?
|
| Heparin | 4 | 2001 | 1636 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2007 | 1470 | 0.060 |
Why?
|
| Neurofibromin 1 | 1 | 2004 | 196 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2005 | 759 | 0.060 |
Why?
|
| Base Sequence | 6 | 2015 | 12797 | 0.060 |
Why?
|
| Intestines | 1 | 2012 | 1923 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 1990 | 971 | 0.050 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2004 | 350 | 0.050 |
Why?
|
| Hormones | 1 | 2006 | 884 | 0.050 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2015 | 300 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 3612 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2003 | 1683 | 0.050 |
Why?
|
| Membrane Lipids | 1 | 2003 | 248 | 0.050 |
Why?
|
| Peptides | 1 | 2014 | 4392 | 0.050 |
Why?
|
| Gingiva | 1 | 2004 | 388 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2011 | 11001 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 2417 | 0.050 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2013 | 1728 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2004 | 572 | 0.050 |
Why?
|
| Cell Lineage | 2 | 2022 | 2504 | 0.050 |
Why?
|
| Calcium Signaling | 2 | 2003 | 721 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 11690 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2005 | 1725 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 4414 | 0.050 |
Why?
|
| Fibroblasts | 2 | 2017 | 4143 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2000 | 142 | 0.050 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 1999 | 17 | 0.050 |
Why?
|
| Gene Knock-In Techniques | 1 | 2021 | 418 | 0.050 |
Why?
|
| Cardiomegaly | 1 | 2003 | 619 | 0.050 |
Why?
|
| Stem Cells | 1 | 2013 | 3563 | 0.050 |
Why?
|
| Kidney Cortex | 1 | 2000 | 186 | 0.040 |
Why?
|
| Urethral Obstruction | 1 | 1999 | 56 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2012 | 21821 | 0.040 |
Why?
|
| Endothelium | 1 | 2022 | 778 | 0.040 |
Why?
|
| Sheep | 1 | 2022 | 1437 | 0.040 |
Why?
|
| Blotting, Western | 4 | 2015 | 5180 | 0.040 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2004 | 838 | 0.040 |
Why?
|
| Trihexosylceramides | 1 | 2018 | 32 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 2001 | 477 | 0.040 |
Why?
|
| Periodicity | 1 | 2000 | 363 | 0.040 |
Why?
|
| Software | 2 | 2024 | 4434 | 0.040 |
Why?
|
| Research Personnel | 1 | 2024 | 573 | 0.040 |
Why?
|
| Genes, erbB-1 | 1 | 1999 | 161 | 0.040 |
Why?
|
| Tumor Microenvironment | 3 | 2017 | 3564 | 0.040 |
Why?
|
| Protein Transport | 2 | 2018 | 1988 | 0.040 |
Why?
|
| Glycosphingolipids | 1 | 2018 | 79 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2015 | 379 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 3 | 2016 | 6382 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2018 | 3127 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 17400 | 0.040 |
Why?
|
| Protein Kinase C | 2 | 2005 | 1227 | 0.040 |
Why?
|
| Glycolipids | 1 | 2018 | 205 | 0.040 |
Why?
|
| Ureteral Obstruction | 1 | 2000 | 293 | 0.040 |
Why?
|
| France | 1 | 2019 | 517 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2018 | 4200 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2019 | 408 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 2 | 2002 | 1525 | 0.040 |
Why?
|
| Models, Biological | 3 | 2012 | 9581 | 0.040 |
Why?
|
| Mutagenicity Tests | 1 | 2017 | 46 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2005 | 1225 | 0.040 |
Why?
|
| Leucovorin | 1 | 2019 | 624 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2003 | 1163 | 0.040 |
Why?
|
| Golgi Apparatus | 1 | 2018 | 410 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2022 | 713 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2005 | 2513 | 0.040 |
Why?
|
| Oxidative Stress | 2 | 2005 | 3081 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 1999 | 694 | 0.040 |
Why?
|
| Gene Expression | 4 | 2003 | 7790 | 0.040 |
Why?
|
| Vitamin B Complex | 1 | 2019 | 288 | 0.040 |
Why?
|
| Hyperplasia | 2 | 2015 | 1183 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 2382 | 0.040 |
Why?
|
| Toxicity Tests | 1 | 2017 | 121 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2015 | 18112 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2016 | 226 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 13655 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 1998 | 396 | 0.030 |
Why?
|
| Cell Tracking | 1 | 2017 | 145 | 0.030 |
Why?
|
| Lymphokines | 1 | 1999 | 949 | 0.030 |
Why?
|
| Extracellular Space | 1 | 1998 | 594 | 0.030 |
Why?
|
| Urine | 1 | 2017 | 370 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 6891 | 0.030 |
Why?
|
| Endosomes | 1 | 2018 | 520 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3920 | 0.030 |
Why?
|
| Proteome | 1 | 2005 | 1790 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 6347 | 0.030 |
Why?
|
| Epothilones | 1 | 2015 | 44 | 0.030 |
Why?
|
| Aging | 1 | 2014 | 8626 | 0.030 |
Why?
|
| Trans-Activators | 2 | 2003 | 2924 | 0.030 |
Why?
|
| Glycosylation | 1 | 2018 | 1123 | 0.030 |
Why?
|
| Animals, Genetically Modified | 2 | 2014 | 1546 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 640 | 0.030 |
Why?
|
| Hydrostatic Pressure | 1 | 2015 | 106 | 0.030 |
Why?
|
| Phylogeny | 1 | 2022 | 2797 | 0.030 |
Why?
|
| Lovastatin | 1 | 2015 | 120 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 2633 | 0.030 |
Why?
|
| Mutation | 3 | 2015 | 29717 | 0.030 |
Why?
|
| Japan | 1 | 2019 | 1360 | 0.030 |
Why?
|
| Receptors, Prostaglandin | 1 | 2014 | 57 | 0.030 |
Why?
|
| Metabolome | 1 | 2021 | 881 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 1999 | 1727 | 0.030 |
Why?
|
| Survival Rate | 2 | 2013 | 12773 | 0.030 |
Why?
|
| Receptors, Purinergic | 1 | 2014 | 66 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2018 | 749 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2019 | 1615 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2022 | 1376 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 10943 | 0.030 |
Why?
|
| Fever | 1 | 2021 | 1612 | 0.030 |
Why?
|
| gamma-Synuclein | 1 | 2013 | 10 | 0.030 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 57683 | 0.030 |
Why?
|
| Receptor, erbB-2 | 2 | 2000 | 2410 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2013 | 3689 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2018 | 1028 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2016 | 798 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 1990 | 4823 | 0.030 |
Why?
|
| Bacterial Toxins | 1 | 2018 | 933 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 905 | 0.030 |
Why?
|
| Urinary Calculi | 1 | 2013 | 91 | 0.030 |
Why?
|
| Protein Precursors | 3 | 2005 | 1154 | 0.030 |
Why?
|
| Lymphatic Vessels | 1 | 2016 | 351 | 0.030 |
Why?
|
| Computational Biology | 1 | 2004 | 3518 | 0.030 |
Why?
|
| Time Factors | 4 | 2010 | 40054 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2013 | 962 | 0.020 |
Why?
|
| Spinal Stenosis | 1 | 2014 | 255 | 0.020 |
Why?
|
| Hip Prosthesis | 1 | 2017 | 917 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2016 | 1124 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 1188 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 6608 | 0.020 |
Why?
|
| Rats, Zucker | 2 | 2000 | 128 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2014 | 721 | 0.020 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2011 | 144 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 9735 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 386 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2011 | 351 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2012 | 563 | 0.020 |
Why?
|
| Myocardium | 1 | 2003 | 4775 | 0.020 |
Why?
|
| Biopsy | 1 | 2021 | 6756 | 0.020 |
Why?
|
| Cell Communication | 1 | 2017 | 1619 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 781 | 0.020 |
Why?
|
| DiGeorge Syndrome | 1 | 2011 | 177 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2010 | 223 | 0.020 |
Why?
|
| Middle Aged | 7 | 2021 | 213127 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2022 | 3455 | 0.020 |
Why?
|
| Polyglycolic Acid | 1 | 2010 | 406 | 0.020 |
Why?
|
| beta Catenin | 1 | 2014 | 1058 | 0.020 |
Why?
|
| Neoplasms | 2 | 2012 | 21596 | 0.020 |
Why?
|
| Calcium | 2 | 2003 | 5753 | 0.020 |
Why?
|
| Blister | 1 | 2009 | 85 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2013 | 670 | 0.020 |
Why?
|
| DNA Replication | 1 | 1996 | 1397 | 0.020 |
Why?
|
| Biological Transport | 1 | 2013 | 2119 | 0.020 |
Why?
|
| Epithelium | 1 | 2013 | 1680 | 0.020 |
Why?
|
| Craniofacial Abnormalities | 1 | 2011 | 315 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 11695 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2721 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2002 | 1799 | 0.020 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2008 | 146 | 0.020 |
Why?
|
| Palmitic Acid | 1 | 2008 | 154 | 0.020 |
Why?
|
| Rabbits | 1 | 2014 | 4886 | 0.020 |
Why?
|
| Pedigree | 1 | 2015 | 4646 | 0.020 |
Why?
|
| Reactive Oxygen Species | 2 | 2005 | 2077 | 0.020 |
Why?
|
| Aged | 6 | 2019 | 162944 | 0.020 |
Why?
|
| Morphogenesis | 1 | 2011 | 752 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1999 | 2522 | 0.020 |
Why?
|
| COS Cells | 1 | 2009 | 1160 | 0.020 |
Why?
|
| Animals, Newborn | 2 | 2003 | 2723 | 0.020 |
Why?
|
| DNA Damage | 1 | 2016 | 2423 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 279 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2022 | 8925 | 0.020 |
Why?
|
| Inflammation | 2 | 2016 | 10578 | 0.020 |
Why?
|
| Benzophenanthridines | 1 | 2005 | 27 | 0.020 |
Why?
|
| Metformin | 1 | 2012 | 829 | 0.020 |
Why?
|
| Adult | 6 | 2021 | 213712 | 0.020 |
Why?
|
| Ovary | 1 | 1990 | 981 | 0.020 |
Why?
|
| In Situ Hybridization | 2 | 2001 | 1950 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2005 | 25575 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 19862 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2019 | 77098 | 0.020 |
Why?
|
| Filipin | 1 | 2003 | 13 | 0.020 |
Why?
|
| Octoxynol | 1 | 2003 | 77 | 0.010 |
Why?
|
| Isotope Labeling | 1 | 2005 | 414 | 0.010 |
Why?
|
| Algorithms | 1 | 2004 | 13853 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 4801 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2005 | 438 | 0.010 |
Why?
|
| Alkaloids | 1 | 2005 | 190 | 0.010 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2003 | 89 | 0.010 |
Why?
|
| Oncogenes | 1 | 2009 | 1263 | 0.010 |
Why?
|
| Swine | 1 | 2013 | 5934 | 0.010 |
Why?
|
| Exocrine Glands | 1 | 2002 | 50 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 2638 | 0.010 |
Why?
|
| Histones | 1 | 2013 | 2597 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 2003 | 379 | 0.010 |
Why?
|
| Rats, Long-Evans | 1 | 2003 | 387 | 0.010 |
Why?
|
| Cell Size | 1 | 2004 | 643 | 0.010 |
Why?
|
| Simvastatin | 1 | 2005 | 360 | 0.010 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2003 | 221 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 188 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 664 | 0.010 |
Why?
|
| Sequence Analysis, Protein | 1 | 2002 | 257 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 2126 | 0.010 |
Why?
|
| Organ Size | 1 | 2006 | 2253 | 0.010 |
Why?
|
| Endocytosis | 1 | 2005 | 983 | 0.010 |
Why?
|
| Tosyl Compounds | 1 | 2001 | 110 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2000 | 67 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2005 | 1251 | 0.010 |
Why?
|
| Leucyl Aminopeptidase | 1 | 2000 | 12 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 2885 | 0.010 |
Why?
|
| Leucine | 1 | 2002 | 560 | 0.010 |
Why?
|
| Parkinson Disease | 1 | 2014 | 2774 | 0.010 |
Why?
|
| Age Distribution | 1 | 2006 | 2900 | 0.010 |
Why?
|
| Sex Factors | 1 | 2014 | 10392 | 0.010 |
Why?
|
| RNA Interference | 1 | 2009 | 2890 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 3847 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2000 | 152 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 1363 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2000 | 134 | 0.010 |
Why?
|
| Prognosis | 2 | 2013 | 29010 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 242 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 12220 | 0.010 |
Why?
|
| Infant | 1 | 2021 | 35070 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2000 | 318 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 3769 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 2088 | 0.010 |
Why?
|
| Antibodies | 1 | 2007 | 2459 | 0.010 |
Why?
|
| Receptor, erbB-3 | 1 | 1999 | 142 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2004 | 1417 | 0.010 |
Why?
|
| Curcumin | 1 | 1999 | 95 | 0.010 |
Why?
|
| Keratins | 1 | 2000 | 515 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11472 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 768 | 0.010 |
Why?
|
| Protective Agents | 1 | 1999 | 156 | 0.010 |
Why?
|
| Anilides | 1 | 2001 | 404 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1999 | 772 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 1999 | 525 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1990 | 8621 | 0.010 |
Why?
|
| Anticholesteremic Agents | 1 | 2005 | 979 | 0.010 |
Why?
|
| Angiotensin II | 1 | 2000 | 881 | 0.010 |
Why?
|
| Phorbol Esters | 1 | 1997 | 111 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 13921 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1998 | 821 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2004 | 1613 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1999 | 1827 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 3691 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 2763 | 0.010 |
Why?
|
| Diphtheria Toxin | 1 | 1997 | 255 | 0.010 |
Why?
|
| Zebrafish | 1 | 2007 | 2990 | 0.010 |
Why?
|
| Nitriles | 1 | 2001 | 952 | 0.010 |
Why?
|
| DNA Probes | 1 | 1997 | 560 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1997 | 549 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 9387 | 0.010 |
Why?
|
| Imidazoles | 1 | 2002 | 1205 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1997 | 1581 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 9185 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1998 | 865 | 0.010 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2000 | 923 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2002 | 2964 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1998 | 1539 | 0.010 |
Why?
|
| Clone Cells | 1 | 1997 | 1692 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1997 | 1574 | 0.010 |
Why?
|
| Tyrosine | 1 | 1997 | 1460 | 0.010 |
Why?
|
| Androgen Antagonists | 1 | 2001 | 1350 | 0.010 |
Why?
|
| Ligands | 1 | 1999 | 3293 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 5522 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1999 | 2906 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1998 | 1504 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 2455 | 0.010 |
Why?
|
| Child | 2 | 2015 | 77478 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 13814 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 40450 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 15494 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1998 | 3770 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2006 | 21719 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1990 | 39004 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 20774 | 0.000 |
Why?
|
| Risk Factors | 1 | 2014 | 72145 | 0.000 |
Why?
|
| RNA | 1 | 1997 | 2747 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2013 | 62966 | 0.000 |
Why?
|
| Child, Preschool | 2 | 1999 | 40955 | 0.000 |
Why?
|
| Bacterial Proteins | 1 | 1997 | 3843 | 0.000 |
Why?
|